TY - JOUR
T1 - COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity
AU - Gragnani, Laura
AU - Visentini, Marcella
AU - Lorini, Serena
AU - Santini, Stefano Angelo
AU - Lauletta, Gianfranco
AU - Mazzaro, Cesare
AU - Urraro, Teresa
AU - Quartuccio, Luca
AU - Cacciapaglia, Fabio
AU - Ruscitti, Piero
AU - Tavoni, Antonio
AU - Marri, Silvia
AU - Cusano, Giuseppina
AU - Petraccia, Luisa
AU - Naclerio, Caterina
AU - Treppo, Elena
AU - Del Frate, Giulia
AU - Di Cola, Ilenia
AU - Raimondo, Vincenzo
AU - Scorpiniti, Daniela
AU - Monti, Monica
AU - Puccetti, Lorenzo
AU - Elia, Giusy
AU - Fallahi, Poupak
AU - Basili, Stefania
AU - Scarpato, Salvatore
AU - Iannone, Florenzo
AU - Casato, Milvia
AU - Antonelli, Alessandro
AU - Zignego, Anna Linda
AU - Ferri, Clodoveo
PY - 2023
Y1 - 2023
N2 - Purpose: Mixed cryoglobulinemia syndrome (MCs) is a rare immunoproliferative systemic disorder with cutaneous and multiple organ involvement. Our multicenter survey study aimed to investigate the prevalence and outcome of COVID-19 and the safety and immunogenicity of COVID-19 vaccines in a large MCs series. Methods: The survey included 430 unselected MCs patients (130 M, 300 F; mean age 70 ± 10.96 years) consecutively collected at 11 Italian referral centers. Disease classification, clinico-serological assessment, COVID-19 tests, and vaccination immunogenicity were carried out according to current methodologies. Results: A significantly higher prevalence of COVID-19 was found in MCs patients compared to Italian general population (11.9% vs 8.0%, p < 0.005), and the use of immunomodulators was associated to a higher risk to get infected (p = 0.0166). Moreover, higher mortality rate was recorded in MCs with COVID-19 compared to those without (p < 0.01). Patients’ older age (≥ 60 years) correlated with worse COVID-19 outcomes. The 87% of patients underwent vaccination and 50% a booster dose. Of note, vaccine-related disease flares/worsening were significantly less frequent than those associated to COVID-19 (p = 0.0012). Impaired vaccination immunogenicity was observed in MCs patients compared to controls either after the first vaccination (p = 0.0039) and also after the booster dose (p = 0.05). Finally, some immunomodulators, namely, rituximab and glucocorticoids, hampered the vaccine-induced immunogenicity (p = 0.029). Conclusions: The present survey revealed an increased prevalence and morbidity of COVID-19 in MCs patients, as well an impaired immunogenicity even after booster vaccination with high rate of no response. Therefore, MCs can be included among frail populations at high risk of infection and severe COVID-19 manifestations, suggesting the need of a close monitoring and specific preventive/therapeutical measures during the ongoing pandemic.
AB - Purpose: Mixed cryoglobulinemia syndrome (MCs) is a rare immunoproliferative systemic disorder with cutaneous and multiple organ involvement. Our multicenter survey study aimed to investigate the prevalence and outcome of COVID-19 and the safety and immunogenicity of COVID-19 vaccines in a large MCs series. Methods: The survey included 430 unselected MCs patients (130 M, 300 F; mean age 70 ± 10.96 years) consecutively collected at 11 Italian referral centers. Disease classification, clinico-serological assessment, COVID-19 tests, and vaccination immunogenicity were carried out according to current methodologies. Results: A significantly higher prevalence of COVID-19 was found in MCs patients compared to Italian general population (11.9% vs 8.0%, p < 0.005), and the use of immunomodulators was associated to a higher risk to get infected (p = 0.0166). Moreover, higher mortality rate was recorded in MCs with COVID-19 compared to those without (p < 0.01). Patients’ older age (≥ 60 years) correlated with worse COVID-19 outcomes. The 87% of patients underwent vaccination and 50% a booster dose. Of note, vaccine-related disease flares/worsening were significantly less frequent than those associated to COVID-19 (p = 0.0012). Impaired vaccination immunogenicity was observed in MCs patients compared to controls either after the first vaccination (p = 0.0039) and also after the booster dose (p = 0.05). Finally, some immunomodulators, namely, rituximab and glucocorticoids, hampered the vaccine-induced immunogenicity (p = 0.029). Conclusions: The present survey revealed an increased prevalence and morbidity of COVID-19 in MCs patients, as well an impaired immunogenicity even after booster vaccination with high rate of no response. Therefore, MCs can be included among frail populations at high risk of infection and severe COVID-19 manifestations, suggesting the need of a close monitoring and specific preventive/therapeutical measures during the ongoing pandemic.
KW - COVID-19 vaccine
KW - SARS-CoV-2
KW - cryoglobulinemic vasculitis
KW - immunogenicity
KW - mixed cryoglobulinemia
KW - COVID-19 vaccine
KW - SARS-CoV-2
KW - cryoglobulinemic vasculitis
KW - immunogenicity
KW - mixed cryoglobulinemia
UR - http://hdl.handle.net/10807/265036
U2 - 10.1007/s10875-023-01444-4
DO - 10.1007/s10875-023-01444-4
M3 - Article
SN - 0271-9142
VL - 43
SP - 680
EP - 691
JO - Journal of Clinical Immunology
JF - Journal of Clinical Immunology
ER -